Encycle Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 6
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $80M
Latest Deal Amount

Encycle Therapeutics General Information

Description

Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's drugs are generated by several scaffolds that are membrane permeable and orally bioavailable products, such as nacellins which are ideal for targeting protein-protein interactions, enabling patients to get cured from inflammatory bowel disease and other inflammatory disorders.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Primary Office
  • 101 College Street
  • Suite 314
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (647) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Encycle Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 23-Oct-2019 $80M 00.000 0000 Completed Generating Revenue
5. Corporate 01-Nov-2017 00000 00.000 Completed Generating Revenue
4. Early Stage VC 30-Sep-2015 00.000 00.000 Completed Startup
3. Early Stage VC 16-Jun-2015 00000 00.000 Completed Startup
2. Grant 17-Nov-2014 $2.5M Completed Startup
1. Early Stage VC 11-Nov-2014 $2.5M $2.5M Completed Startup
To view Encycle Therapeutics’s complete valuation and funding history, request access »

Encycle Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's dru
Drug Discovery
Toronto, Canada
6 As of 2015
00.000
000 0000-00-00
000000&0 00.000

00000000

adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad mini
0000 000000000
Vienna, Austria
00.000
0000000000 00.000

00000000

ris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate vel
0000000000000
Cambridge, MA
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Encycle Therapeutics Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apeptico Forschung und Entwicklung Venture Capital-Backed Vienna, Austria 00.000 0000000000 00.000
00000000 Venture Capital-Backed Cambridge, MA 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Boston, MA 00 00000 000000 - 000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000 000000 Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 20 competitors. Get the full list »

Encycle Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Jeffrey Coull Ph.D Chief Executive Officer & President
To view Encycle Therapeutics’s complete executive team members history, request access »

Encycle Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Encycle Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Accel-Rx Accelerator/Incubator Minority 000 0000 000000 0
BDC Capital Venture Capital Minority 000 0000 000000 0
CQDM Other Minority 000 0000 000000 0
MaRS Investment Accelerator Fund Venture Capital Minority 000 0000 000000 0
Merck & Co. Corporation 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »